Oncolytic virotherapy for malignant glioma: Translating laboratory insights into clinical practice

Frontiers in Oncology

Volumn 3 FEB, Issue , 2013, Pages

  Auffinger, Brenda ^a   Ahmed, Atique U ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer stem cells; Challenges; Immunomodulation; Malignant glioma; Oncolytic virotherapy

Indexed keywords

AD5 DELTA24; ANTINEOPLASTIC AGENT; CONDITIONALLY REPLICATING ADENOVIRUS; DELTA 24 ARGINYLGLYCYLASPARTIC ACID; ETOPOSIDE; G 207; G47DELTA; GANCICLOVIR; INTERLEUKIN 2; INTERLEUKIN 4; IRINOTECAN; LONTUCIREV; ONCOLYTIC HERPES VIRUS; PELAREOREP; SITIMAGENE CERADENOVEC; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VANCYCLOVIR;

ABSENCE OF SIDE EFFECTS; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE CHECKPOINT; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 84888036694     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00032     Document Type: Review

References (120)

1. Abordo-Adesida, E., Follenzi, A., Barcia, C., Sciascia, S., Castro, M. G., Naldini, L., et al. (2005). Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum. Gene Ther. 16, 741-751.
2. Ahmed, A. U., Thaci, B., Alexiades, N. G., Han, Y., Qian, S., Liu, F., et al. (2011a). Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol. Ther. 19, 1714-1726.
3. Ahmed, A. U., Tyler, M. A., Thaci, B., Alexiades, N. G., Han, Y., Ulasov, I. V., et al. (2011b). A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol. Pharm. 8, 1559-1572.
4. Alonso, M. M., Jiang, H., Gomez-Manzano, C., and Fueyo, J. (2012). Targeting brain tumor stem cells with oncolytic adenoviruses. Methods Mol. Biol. 797, 111-125.
5. Andreansky, S., He, B., van Cott, J., McGhee, J., Markert, J. M., Gillespie, G. Y., et al. (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5, 121-130.
6. Balachandran, S., and Barber, G. N. (2004). Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5, 51-65.
7. Bansal, K., and Engelhard, H. H. (2000). Gene therapy for brain tumors. Curr. Oncol. Rep. 2, 463-472.
8. Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
9. Biederer, C., Ries, S., Brandts, C. H., and McCormick, F. (2002). Replication-selective viruses for cancer therapy. J. Mol. Med. (Berl.) 80, 163-175.
10. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
11. Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., and Oldfield, E. H. (1994). Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U.S.A. 91, 2076-2080.
12. Brinckerhoff, C. E., and Matrisian, L. M. (2002). Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 3, 207-214.
13. Brown, A. B., Yang, W., Schmidt, N. O., Carroll, R., Leishear, K. K., Rainov, N. G., et al. (2003). Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum. Gene Ther. 14, 1777-1785.
14. Candolfi, M., Curtin, J. F., Nichols, W. S., Muhammad, A. G., King, G. D., Pluhar, G. E., et al. (2007). Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J. Neurooncol. 85, 133-148.
15. Cheema, T. A., Kanai, R., Kim, G. W., Wakimoto, H., Passer, B., Rabkin, S. D., et al. (2011). Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin. Cancer Res. 17, 7383-7393.
16. Chen, C. Y., Chang, Y. N., Ryan, P., Linscott, M., McGarrity, G. J., and Chiang, Y. L. (1995). Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the bystander effect. Hum. Gene Ther. 6, 1467-1476.
17. Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., et al. (2004). A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 10, 958-966.
18. Chiocca, E. A., Aguilar, L. K., Bell, S. D., Kaur, B., Hardcastle, J., Cavaliere, R., et al. (2011). Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J. Clin. Oncol. 29, 3611-3619.
19. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
20. Coffey, M. C., Strong, J. E., Forsyth, P. A., and Lee, P. W. (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334.
21. Curtin, J. F., Liu, N., Candolfi, M., Xiong, W., Assi, H., Yagiz, K., et al. (2009). HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6:e10. doi: 10.1371/journal.pmed.1000010
22. Dean, M., Fojo, T., and Bates, S. (2005). Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284.
23. Dey, M., Ulasov, I. V., Tyler, M. A., Sonabend, A. M., and Lesniak, M. S. (2011). Cancer stem cells: the final frontier for glioma virotherapy. Stem. Cell Rev. 7, 119-129.
24. Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., et al. (2007). AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477.
25. Finkelstein, S. D., Black, P., Nowak, T. P., Hand, C. M., Christensen, S., and Finch, P. W. (1994). Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. Neurosurgery 34, 136-143.
26. Fomchenko, E. I., and Holland, E. C. (2006). Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res. 12, 5288-5297.
27. Forsyth, P., Roldan, G., George, D., Wallace, C., Palmer, C. A., Morris, D., et al. (2008). A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol. Ther. 16, 627-632.
28. Friedman, A., Tian, J. P., Fulci, G., Chiocca, E. A., and Wang, J. (2006). Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res. 66, 2314-2319.
29. Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., et al. (2003). Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst. 95, 652-660.
30. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12.
31. Fueyo, J., Gomez-Manzano, C., Yung, W. K., and Kyritsis, A. P. (1999). Targeting in gene therapy for gliomas. Arch. Neurol. 56, 445-448.
32. Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 103, 12873-12878.
33. Fulci, G., Dmitrieva, N., Gianni, D., Fontana, E. J., Pan, X., Lu, Y., et al. (2007). Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 67, 9398-9406.
34. Galea-Lauri, J., Farzaneh, F., and Gaken, J. (1996). Novel costimulators in the immune gene therapy of cancer. Cancer Gene Ther. 3, 202-214.
35. Ganesh, S., Gonzalez-Edick, M., Gibbons, D., Van Roey, M., and Jooss, K. (2008). Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin. Cancer Res. 14, 3933-3941.
36. Ganesh, S., Gonzalez Edick, M., Idamakanti, N., Abramova, M., Vanroey, M., Robinson, M., et al. (2007). Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 67, 4399-4407.
37. Geoerger, B., Grill, J., Opolon, P., Morizet, J., Aubert, G., Terrier-Lacombe, M. J., et al. (2002). Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 62, 764-772.
38. Gomez-Manzano, C., Balague, C., Alemany, R., Lemoine, M. G., Mitlianga, P., Jiang, H., et al. (2004). A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23, 1821-1828.
39. Gomez-Manzano, C., Jiang, H., Alonso, M., Yung, W. K., and Fueyo, J. (2012). Gene therapy. Handb. Clin. Neurol. 104, 331-338.
40. Grossman, S. A., Ye, X., Piantadosi, S., Desideri, S., Nabors, L. B., Rosenfeld, M., et al. (2010). Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16, 2443-2449.
41. Hamburger, A. W., and Salmon, S. E. (1977). Primary bioassay of human tumor stem cells. Science 197, 461-463.
42. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139.
43. Hellums, E. K., Markert, J. M., Parker, J. N., He, B., Perbal, B., Roizman, B., et al. (2005). Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro. Oncol. 7, 213-224.
44. Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323.
45. Hu, X., and Holland, E. C. (2005). Applications of mouse glioma models in preclinical trials. Mutat. Res. 576, 54-65.
46. Hunt, K. K., and Vorburger, S. A. (2002). Tech.Sight. Gene therapy. Hurdles and hopes for cancer treatment. Science 297, 415-416.
47. Iankov, I. D., Blechacz, B., Liu, C., Schmeckpeper, J. D., Tarara, J. E., Federspiel, M. J., et al. (2007). Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol. Ther. 15, 114-122.
48. Ilett, E. J., Prestwich, R. J., Kottke, T., Errington, F., Thompson, J. M., Harrington, K. J., et al. (2009). Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 16, 689-699.
49. Immonen, A., Vapalahti, M., Tyynela, K., Hurskainen, H., Sandmair, A., Vanninen, R., et al. (2004). AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 10, 967-972.
50. Jiang, H., Conrad, C., Fueyo, J., Gomez-Manzano, C., and Liu, T. J. (2003). Oncolytic adenoviruses for malignant glioma therapy. Front. Biosci. 8, d577-d588.
51. Jiang, H., Gomez-Manzano, C., Alemany, R., Medrano, D., Alonso, M., Bekele, B. N., et al. (2005). Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7, 48-56.
52. Jiang, H., Gomez-Manzano, C., Aoki, H., Alonso, M. M., Kondo, S., McCormick, F., et al. (2007). Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J. Natl. Cancer Inst. 99, 1410-1414.
53. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., et al. (2000). a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
54. Kim, J. H., Lee, Y. S., Kim, H., Huang, J. H., Yoon, A. R., and Yun, C. O. (2006). Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst. 98, 1482-1493.
55. Kim, M., Chung, Y. H., and Johnston, R. N. (2007). Reovirus and tumor oncolysis. J. Microbiol. 45, 187-192.
56. Kohno, S., Nakagawa, K., Hamada, K., Harada, H., Yamasaki, K., Hashimoto, K., et al. (2004). Midkine promoter-based conditionally replicative adenovirus for malignant glioma therapy. Oncol. Rep. 12, 73-78.
57. Komata, T., Kondo, Y., Kanzawa, T., Hirohata, S., Koga, S., Sumiyoshi, H., et al. (2001). Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 61, 5796-5802.
58. Kottke, T., Hall, G., Pulido, J., Diaz, R. M., Thompson, J., Chong, H., et al. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J. Clin. Invest. 120, 1551-1560.
59. Kuriyama, N., Kuriyama, H., Julin, C. M., Lamborn, K., and Israel, M. A. (2000). Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum. Gene Ther. 11, 2219-2230.
60. Kurozumi, K., Hardcastle, J., Thakur, R., Yang, M., Christoforidis, G., Fulci, G., et al. (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl. Cancer Inst. 99, 1768-1781.
61. Lamfers, M. L., Grill, J., Dirven, C. M., Van Beusechem, V. W., Geoerger, B., Van Den Berg, J., et al. (2002). Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 62, 5736-5742.
62. Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., et al. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 21, 2508-2518.
63. Lin, E., and Nemunaitis, J. (2004). Oncolytic viral therapies. Cancer Gene Ther. 11, 643-664.
64. Maillard, L., Ziol, M., Tahlil, O., Le Feuvre, C., Feldman, L. J., Branellec, D., et al. (1998). Pre-treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media. Gene Ther. 5, 1023-1030.
65. Mardor, Y., Rahav, O., Zauberman, Y., Lidar, Z., Ocherashvilli, A., Daniels, D., et al. (2005). Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res. 65, 6858-6863.
66. Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17, 199-207.
67. Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867-874.
68. McKee, T. D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J. P., et al. (2006). Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66, 2509-2513.
69. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943.
70. Mizuno, H., Yanoma, S., Nishimura, G., Hattori, S., Ito, T., Okudera, K., et al. (2000). Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma. Cancer Lett. 152, 175-185.
71. Mok, W., Boucher, Y., and Jain, R. K. (2007). Matrix metalloproteinases-1 and-8 improve the distribution and efficacy of an oncolytic virus. Cancer Res. 67, 10664-10668.
72. Nandi, S., Ulasov, I. V., Tyler, M. A., Sugihara, A. Q., Molinero, L., Han, Y., et al. (2008). Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res. 68, 5778-5784.
73. Neuwelt, E. A. (1980). Reversible osmotic blood-brain barrier disruption in humans: implications for the chemotherapy of malignant brain tumors. Neurosurgery 7, 204.
74. Otsuki, A., Patel, A., Kasai, K., Suzuki, M., Kurozumi, K., Chiocca, E. A., et al. (2008). Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther. 16, 1546-1555.
75. Parker, J. N., Bauer, D. F., Cody, J. J., and Markert, J. M. (2009). Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6, 558-569.
76. Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., and Markert, J. M. (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. U.S.A. 97, 2208-2213.
77. Pelengaris, S., Littlewood, T., Khan, M., Elia, G., and Evan, G. (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565-577.
78. Post, D. E., Sandberg, E. M., Kyle, M. M., Devi, N. S., Brat, D. J., Xu, Z., et al. (2007). Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 67, 6872-6881.
79. Post, D. E., and Van Meir, E. G. (2003). A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22, 2065-2072.
80. Power, A. T., Wang, J., Falls, T. J., Paterson, J. M., Parato, K. A., Lichty, B. D., et al. (2007). Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 15, 123-130.
81. Qiao, J., Kottke, T., Willmon, C., Galivo, F., Wongthida, P., Diaz, R. M., et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat. Med. 14, 37-44.
82. Quinlan, M. P., Quatela, S. E., Philips, M. R., and Settleman, J. (2008). Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol. Cell. Biol. 28, 2659-2674.
83. Raykov, Z., Balboni, G., Aprahamian, M., and Rommelaere, J. (2004). Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int. J. Cancer 109, 742-749.
84. Ren, H., Boulikas, T., Lundstrom, K., Soling, A., Warnke, P. C., and Rainov, N. G. (2003). Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J. Neurooncol. 64, 147-154.
85. Rosenberg, S. A., Yang, J. C., and Restifo, N. P. (2004). Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915.
86. Sandmair, A. M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., et al. (2000). Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11, 2197-2205.
87. Shapiro, W. R., Basler, G. A., Chernik, N. L., and Posner, J. B. (1979). Human brain tumor transplantation into nude mice. J. Natl. Cancer Inst. 62, 447-453.
88. Sonabend, A. M., Ulasov, I. V., Han, Y., Rolle, C. E., Nandi, S., Cao, D., et al. (2009). Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther. 16, 362-372.
89. Sonabend, A. M., Ulasov, I. V., Tyler, M. A., Rivera, A. A., Mathis, J. M., and Lesniak, M. S. (2008). Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26, 831-841.
90. Stanford, M. M., Barrett, J. W., Gilbert, P. A., Bankert, R., and McFadden, G. (2007). Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. J. Virol. 81, 12704-12708.
91. Stanley, K. (2007). Design of randomized controlled trials. Circulation 115, 1164-1169.
92. Streck, C. J., Dickson, P. V., Ng, C. Y., Zhou, J., Hall, M. M., Gray, J. T., et al. (2006). Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther. 13, 99-106.
93. Strong, J. E., Coffey, M. C., Tang, D., Sabinin, P., and Lee, P. W. (1998). The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 17, 3351-3362.
94. Stupp, R., and Hegi, M. E. (2007). Targeting brain-tumor stem cells. Nat. Biotechnol. 25, 193-194.
95. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
96. Stupp, R., and Roila, F. (2009). Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 126-128.
97. Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T., and Alemany, R. (2001). A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 7, 120-126.
98. Thomas, D. L., and Fraser, N. W. (2003). HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol. Ther. 8, 543-551.
99. Thorne, S. H., Negrin, R. S., and Contag, C. H. (2006). Synergistic antitumor effects of immune cell-viral biotherapy. Science 311, 1780-1784.
100. Todo, T. (2012). Active immunotherapy: oncolytic virus therapy using HSV-1. Adv. Exp. Med. Biol. 746, 178-186.
101. Todo, T., Martuza, R. L., Dallman, M. J., and Rabkin, S. D. (2001a). In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 61, 153-161.
102. Todo, T., Martuza, R. L., Rabkin, S. D., and Johnson, P. A. (2001b). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U.S.A. 98, 6396-6401.
103. Todo, T., Rabkin, S. D., Sundaresan, P., Wu, A., Meehan, K. R., Herscowitz, H. B., et al. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10, 2741-2755.
104. Tyler, M. A., Ulasov, I. V., Sonabend, A. M., Nandi, S., Han, Y., Marler, S., et al. (2009). Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 16, 262-278.
105. Ulasov, I. V., Rivera, A. A., Nettelbeck, D. M., Rivera, L. B., Mathis, J. M., Sonabend, A. M., et al. (2007a). An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. Int. J. Oncol. 31, 1177-1185.
106. Ulasov, I. V., Rivera, A. A., Sonabend, A. M., Rivera, L. B., Wang, M., Zhu, Z. B., et al. (2007b). Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol. Ther. 6, 679-685.
107. Ulasov, I. V., Zhu, Z. B., Tyler, M. A., Han, Y., Rivera, A. A., Khramtsov, A., et al. (2007c). Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum. Gene Ther. 18, 589-602.
108. Ulasov, I. V., Tyler, M. A., Rivera, A. A., Nettlebeck, D. M., Douglas, J. T., and Lesniak, M. S. (2008). Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. J. Med. Virol. 80, 1595-1603.
109. van Beusechem, V. W., Grill, J., Mastenbroek, D. C., Wickham, T. J., Roelvink, P. W., Haisma, H. J., et al. (2002). Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J. Virol. 76, 2753-2762.
110. Van Houdt, W. J., Haviv, Y. S., Lu, B., Wang, M., Rivera, A. A., Ulasov, I. V., et al. (2006). The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J. Neurosurg. 104, 583-592.
111. Vandier, D., Rixe, O., Besnard, F., Kim, M., Rikiyama, T., Goldsmith, M., et al. (2000). Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 7, 1120-1126.
112. Wakimoto, H., Johnson, P. R., Knipe, D. M., and Chiocca, E. A. (2003). Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10, 983-990.
113. Wakimoto, H., Kesari, S., Farrell, C. J., Curry, W. T. Jr., Zaupa, C., Aghi, M., et al. (2009). Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 69, 3472-3481.
114. Wang, W., Zhu, N. L., Chua, J., Swenson, S., Costa, F. K., Schmitmeier, S., et al. (2005). Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. J. Neurosurg. 103, 1058-1066.
115. Wen, P. Y., and Kesari, S. (2008). Malignant gliomas in adults. N. Engl. J. Med. 359, 492-507.
116. Yang, W. Q., Lun, X., Palmer, C. A., Wilcox, M. E., Muzik, H., Shi, Z. Q., et al. (2004). Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin. Cancer Res. 10, 8561-8576.
117. Yang, W. Q., Senger, D., Muzik, H., Shi, Z. Q., Johnson, D., Brasher, P. M., et al. (2003). Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res. 63, 3162-3172.
118. Yong, R. L., Shinojima, N., Fueyo, J., Gumin, J., Vecil, G. G., Marini, F. C., et al. (2009). Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 69, 8932-8940.
119. Zhang, X., Komaki, R., Wang, L., Fang, B., and Chang, J. Y. (2008). Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin. Cancer Res. 14, 2813-2823.
120. Zhu, Z. B., Makhija, S. K., Lu, B., Wang, M., Rivera, A. A., Kim-Park, S., et al. (2005). Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int. J. Oncol. 27, 237-246.